Primer: TransThera Sciences (Nanjing) (2617 HK) - Aug 2026
TransThera is a clinical-stage biopharmaceutical company with a pipeline focused on high-unmet-need areas, led by its core asset, Tinengotinib,...
96 Views
𝛼SK or SearchENTITY
TransThera Sciences (Nanjing) (2617 HK)
TransThera Sciences (Nanjing) (2617 HK)
43
Analysis
Health Care • China
TransThera Sciences (Nanjing) Inc. is a China-based biopharmaceutical company focused on discovering and developing innovative small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. Its core product, Tinengotinib (TT-00420), is a multi-targeted kinase (MTK) inhibitor in clinical stages for treating relapsed or refractory, drug-resistant solid tumors. The company is headquartered in Nanjing, China, and was founded in 2014.
morex